NeoGenomics (NASDAQ:NEO) Sets New 12-Month High – Here’s What Happened

Posted by Stanley Muller on Aug 10th, 2026

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $16.64 and last traded at $16.5080, with a volume of 1224 shares changing hands. The stock had previously closed at $16.57.

Analysts Set New Price Targets

NEO has been the topic of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Wednesday, July 15th. Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $12.00 to $25.00 in a research note on Wednesday, April 29th. Zacks Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Weiss Ratings upgraded NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. Finally, Craig Hallum reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

View Our Latest Report on NEO

NeoGenomics Trading Up 2.0%

The company has a quick ratio of 3.35, a current ratio of 3.60 and a debt-to-equity ratio of 0.48. The company has a market cap of $2.17 billion, a P/E ratio of -42.06 and a beta of 1.74. The business has a 50-day moving average price of $13.40 and a two-hundred day moving average price of $10.82.

NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.02. The business had revenue of $201.66 million for the quarter, compared to analysts’ expectations of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The firm’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 earnings per share. On average, analysts predict that NeoGenomics, Inc. will post -0.09 EPS for the current year.

Insider Transactions at NeoGenomics

In other news, Director Lynn A. Tetrault sold 5,307 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total value of $59,916.03. Following the transaction, the director owned 91,422 shares of the company’s stock, valued at approximately $1,032,154.38. This trade represents a 5.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On NeoGenomics

Several institutional investors have recently modified their holdings of NEO. First Horizon Corp lifted its stake in NeoGenomics by 52.6% in the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 865 shares during the last quarter. State of Alaska Department of Revenue increased its stake in shares of NeoGenomics by 1.7% during the 4th quarter. State of Alaska Department of Revenue now owns 73,044 shares of the medical research company’s stock worth $858,000 after purchasing an additional 1,215 shares during the last quarter. Choreo LLC increased its stake in shares of NeoGenomics by 2.2% during the 4th quarter. Choreo LLC now owns 61,462 shares of the medical research company’s stock worth $752,000 after purchasing an additional 1,313 shares during the last quarter. Entropy Technologies LP raised its holdings in shares of NeoGenomics by 6.9% in the 4th quarter. Entropy Technologies LP now owns 23,037 shares of the medical research company’s stock valued at $271,000 after purchasing an additional 1,480 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in shares of NeoGenomics by 77.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,515 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

About NeoGenomics

(Get Free Report)

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.